FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
AMES, Iowa, Nov. 09, 2016 -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with cancer, today announced that it will participate in the Global Mizuho Investor Conference on November 14, the Stifel 2016 Healthcare Conference on November 15 and the Piper Jaffray 28th Annual Healthcare Conference on November 29, all to be held in New York City.
A live webcast of the presentations, if available, will be on the Company's website at www.newlinkgenetics.com in the "Investors & Media" section under "Events and Presentations."
About NewLink Genetics Corporation
NewLink Genetics is a biopharmaceutical company at the forefront of discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' product candidates are designed to harness multiple components of the immune system to combat cancer. For more information, please visit http://www.newlinkgenetics.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of NewLink Genetics that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release are forward-looking statements, within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "target," "potential," "will," "could," "should," "seek" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include any statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that NewLink Genetics makes due to a number of important factors, including those risks discussed in "Risk Factors" and elsewhere in NewLink Genetics' Annual Report on Form 10-K for the year ended December 31, 2015 and other reports filed with the U.S. Securities and Exchange Commission (SEC). The forward-looking statements in this press release represent NewLink' Genetics' views as of the date of this press release. NewLink Genetics anticipates that subsequent events and developments will cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing NewLink Genetics' views as of any date subsequent to the date of this press release.
Contact: Jack Henneman EVP, CFO (515) 598-2561 [email protected] Investor and Media Contacts: Beth Kurth, VP LaVoieHealthScience (617) 374-8800, ext. 106 [email protected] Ben Navon, AVP LaVoieHealthScience (617) 374-8800, ext. 108 [email protected]
